바로가기  >

Abstract
The aim of this work was to evaluate a tumor-targeting porphyrin-based gadolinium complex (Gd-TDAP) for use as an MR/optical imaging agent and potential therapeutic agent. Gd-TDAP had higher longitudinal relaxivity (11.8 mM-1 s-1) than a commercial MRI contrast agent (Omniscan; 3.7 mM-1 s-1) in HSA solution (0.67 mM) at 3 T. The tumor-targeting characteristics were confirmed by T1-weighted MR imaging and optical imaging using an orthotopic brain tumor mouse model, which showed 1.3-fold higher uptake in tumor compared to normal brain tissues. The cell fraction data using U87MG glioblastoma cells indicated the potential for gadolinium neutron capture therapy (Gd-NCT), which requires gadolinium to be inside the cell nucleus. In addition, porphyrin derivatives can be used for photodynamic therapy (PDT), and the results demonstrated that Gd-TDAP has great potential not only as a bimodal imaging agent but also for treatment.

Affiliations

Soyeon Kim 1 2, Ji-Ung Yang 1 2, Jae Hun Ahn 1 3, In Ok Ko 1, Jung Young Kim 1, Yong Jin Lee 1, Ji-Ae Park 1
1Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS), Seoul 01812, Korea.
2Department of Medical & Biological Engineering, Kyungpook National University, Daegu 41566, Korea.
3Graduate School of Translational Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.